In the later of 21st, Feb., the strategic cooperation agreement signing ceremony takes place in Chengdu. By capital investment, China Taihe becomes key stakeholder to 3 subsidiaries under the Sichuan Hebang Group. In return, Sichuan Hebang Group sell part of its shares to China Taihe and acquired the latter’s investment. This joint agreement will bring mutual advantages to either side, aiming to create a high specialized OTC brand, boosting the development of TCM industry.

    As the very 1st Sichuan Acquisition case in 2017, this, driven by social capital, became a significant event manifesting the flourishing TCM industry in the long known chinese traditional medicine province. 

    The attendees are Chairman of China Taihe - Mr. Wang Renguo, The senior managers and department directors of Sichuan Taihe. Sichuan Hebang Group: Chairman – Liu Wenxu, Deputy Chairman Liu Yongfeng, President Yang Tao and other relevant department directors.

   China Taihe Group was founded in 1995. After over 20 years’ extraordinary industrial development and capital management, it has formed a layout of "Prominent Financial Industry, Co-developed Health, Cultural Tourism, Real Estate, Agriculture and other related industries". The Group is holding shares of a number of listed companies, 2 private banks, possessing and managing 21 managing high-star and theme hotels. In addition, it is shareholder of a number of financial institutions and more than 30 subsidiaries in different types. In the Healthcare aspect, Taihe has accumulated an astonishing records, being the principal stakeholder of Chengdu Taihe Healthcare Technology Group(listed in August of 2015), acquisition of Sichuan Intercontinental Gastrointestinal and Anorectal Diseases Specialist Hospital, Intercontinental Traditional Chinese Medicine Treatment Hospital, making its healthcare system more sophisticated.

   Sichuan Hebang Group, established since 1999, is a comprehensive private medical enterprise specializing Chinese medicine cultivation, research, sales. Hebang owns a long list of Chinese medicine manufacturer, wholly-owns and holds over  30 subsidiaries, 18 pharmaceutical companies, 12 sales company, 23 preparations, Chinese patent medicine output over 2 millions packs, 56 proprietary intellectual property rights, more than 100 types of medicine recorded by national authorities. In addition, it has taken lead in building the Ziyang Biological Medical Technology Park, Lanzhou Chinese Medicine Modernization Park.

   This alliance, driven by capital investment and industrial superiority, is to be further employed in the ecological healthcare industry project, promoting the traditional Chinese medicine industry as a comprehensive system serving for healthcare, medicine care, rehabilitation care, boosting the local economic development, contributing to the Chinese health building.